Results 131 to 140 of about 22,236,668 (323)

Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial

open access: yesJournal of Orthopaedic Surgery and Research, 2017
Background This study was conducted to assess the efficacy and safety of the three dose levels of the three-dimensional autologous chondrocyte implantation product chondrosphere® in the treatment of cartilage defects (4–10 cm2) of knee joints.
Christoph Becher   +9 more
doaj   +1 more source

From patient advocacy to patient‐driven research: Building active partnerships beginning at the bench to reach the bedside

open access: yesFEBS Open Bio, EarlyView.
Research is strongest when conducted alongside patients, not just about them. Patient research organizations help integrate patient perspectives into research priorities, study design, and scientific meetings, leading to meaningful patient outcomes and development of relevant therapies.
Jenica H. Kakadia   +9 more
wiley   +1 more source

Toxicity in the era of immune checkpoint inhibitor therapy

open access: yesFrontiers in Immunology
Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4).
Synat Keam   +20 more
doaj   +1 more source

A structural equation model of adverse events and length of stay in hospitals [PDF]

open access: yes
Adverse events in hospitals cause significant morbidity and mortality, and considerable effort has been invested into analysing their incidence and preventability. An unresolved issue in models of medical adverse events is potential endogeneity of length
Katharina Hauck, Xueyan Zhao
core  

Related adverse events in treatment groups with or without IL-12 pDNA adjuvant.

open access: yes, 2018
Related adverse events in treatment groups with or without IL-12 pDNA adjuvant.
Magdalena E. Sobieszczyk (332353)   +18 more
core   +1 more source

Adverse events of nintedanib treatment.

open access: yes, 2022
Adverse events of nintedanib treatment.
Yumi Yoshikawa (5461178)   +9 more
core   +1 more source

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

open access: yesFEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain   +11 more
wiley   +1 more source

Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy

open access: yesDiagnostics
Background/Objectives: Immunotherapy and targeted therapy have revolutionized the treatment of advanced cutaneous melanoma. However, predicting individual response and managing resistance remain major challenges.
Federico Venturi   +13 more
doaj   +1 more source

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events

open access: yesChinese Journal of Lung Cancer, 2019
Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs).
Junling ZHUANG   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy